Microba Life Sciences Limited (AU:MAP)
ASX:MAP
Want to see AU:MAP full AI Analyst Report?
Top Page
Microba Life Sciences Limited
(Sydney:MAP)
Select Model
Select Model
Rating:40Underperform
Price Target:
AU$0.06
▼(-25.00% Downside)
Action:Downgraded
Date:06/04/26
Overall score is pressured primarily by weak financial performance (declining revenue, persistent losses, and negative operating cash flow). Technicals add further downside risk with the price below major moving averages and negative MACD, while valuation is constrained by a negative P/E and no dividend yield data.
Positive Factors
Low leverage / strong equity base
A very low debt-to-equity ratio provides durable financial flexibility, reducing short-term refinancing risk and preserving capacity to fund R&D, platform development or strategic partnerships over the next 2–6 months without immediate debt pressure.
Negative Factors
Declining revenue and persistent losses
Substantial revenue decline combined with ongoing operating losses weakens internal funding capacity and undermines margin recovery prospects. Over a 2–6 month horizon this reduces headroom for commercial scaling and increases likelihood of needing external capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong equity base
A very low debt-to-equity ratio provides durable financial flexibility, reducing short-term refinancing risk and preserving capacity to fund R&D, platform development or strategic partnerships over the next 2–6 months without immediate debt pressure.
Read all positive factors
Microba Life Sciences Limited (MAP) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$38.36M
Dividend YieldN/A
Average Volume (3M)469.77K
Price to Earnings (P/E)―
Beta (1Y)1.09
Revenue Growth-11.81%
EPS Growth-21.45%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.04
Shares Outstanding608,963,000
10 Day Avg. Volume548,444
30 Day Avg. Volume469,774
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.17
Price to Sales (P/S)2.43
P/FCF Ratio-2.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.14Price Target Upside68.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.02
Revenue Forecast (FY)AU$16.80M
Microba Life Sciences Limited Business Overview & Revenue Model
Company Description
Microba Life Sciences Limited provides microbiome testing and analysis services for clinicians, consumers, and research customers in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, and the United States. It offers pat...
How the Company Makes Money
Microba makes money primarily by selling microbiome testing and analysis services and by earning revenue from collaborations that leverage its microbiome measurement and discovery platform.
Key revenue streams include:
1) Clinical and consumer mi...
Microba Life Sciences Limited Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
45
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.90M | 15.67M | 12.09M | 5.42M | 4.69M | 3.73M |
| Gross Profit | -2.96M | 7.44M | 5.91M | -6.77M | 2.37M | -5.30M |
| EBITDA | -21.64M | -10.51M | -17.10M | -17.07M | -9.86M | -6.28M |
| Net Income | -19.75M | -14.94M | -19.94M | -12.68M | -11.47M | -7.52M |
Balance Sheet | ||||||
| Total Assets | 43.35M | 47.44M | 58.04M | 46.95M | 39.48M | 18.49M |
| Cash, Cash Equivalents and Short-Term Investments | 11.27M | 11.74M | 20.89M | 32.04M | 30.79M | 13.03M |
| Total Debt | 3.31M | 3.23M | 1.58M | 1.14M | 1.33M | 269.02K |
| Total Liabilities | 12.27M | 14.94M | 16.82M | 8.23M | 5.94M | 3.55M |
| Stockholders Equity | 30.18M | 32.49M | 41.22M | 38.57M | 33.54M | 14.94M |
Cash Flow | ||||||
| Free Cash Flow | -15.38M | -14.91M | -19.95M | -15.43M | -12.32M | -7.85M |
| Operating Cash Flow | -15.05M | -12.01M | -15.57M | -12.39M | -10.45M | -7.18M |
| Investing Cash Flow | -3.39M | -2.83M | -13.95M | -3.00M | -1.73M | -522.48K |
| Financing Cash Flow | 12.34M | 5.58M | 18.39M | 16.68M | 29.22M | 13.84M |
Microba Life Sciences Limited Technical Analysis
Negative
0.08
Price Trends
0.07
Negative
0.08
Negative
0.08
Negative
Market Momentum
>-0.01
Positive
16.07
Positive
-3.33
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:MAP, the sentiment is Negative. The current price of 0.08 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.07, and below the 200-day MA of 0.08, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 16.07 is Positive, neither overbought nor oversold. The STOCH value of -3.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:MAP.
Microba Life Sciences Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$97.57M | -6.49 | -164.12% | ― | -14.85% | -41.04% | |
44 Neutral | AU$5.67M | -0.45 | -184.98% | ― | ― | ― | |
41 Neutral | AU$40.05M | -5.48 | -476.27% | ― | ― | -142.39% | |
40 Underperform | AU$38.36M | -1.87 | -63.04% | ― | -11.81% | -21.45% | |
40 Underperform | AU$28.76M | -3.84 | -164.22% | ― | ― | 26.04% | |
39 Underperform | AU$15.67M | -1.39 | -23.93% | ― | 9.69% | 52.31% |
* Healthcare Sector Average
AU:MAP
Microba Life Sciences Limited
0.06
-0.07
-51.54%
AU:GTG
Genetic Technologies
0.04
0.00
0.00%
AU:BDX
BCAL Diagnostics Limited
0.08
>-0.01
-6.25%
AU:RHY
Rhythm Biosciences Ltd.
0.12
0.05
88.52%
AU:LDX
Lumos Diagnostics Holdings Ltd.
0.11
0.08
266.67%
AU:GSS
Genetic Signatures Ltd.
0.07
-0.39
-85.43%
Microba Life Sciences Limited Corporate Events
Microba halts ASX trading ahead of capital raise and breakeven update
Jun 3, 2026
Microba Life Sciences Limited, a microbiome-focused health sciences company, develops clinical-grade microbiome testing solutions designed to support healthier lives. The Brisbane-based firm leverages world-leading science and analytical tools to ...
Microba Life Sciences Options Lapse, Trimming Potential Dilution
Apr 30, 2026
Microba Life Sciences Limited has updated the market on changes to its issued capital following the expiry of certain options on its register. The company reported that a total of 3,066,666 options, each exercisable at $0.3242 and due to expire in...
Microba Launches Q3 FY26 Investor Webinar and Expands Interactive Investor Hub
Apr 30, 2026
Microba Life Sciences Limited has released its Q3 FY26 investor presentation and announced a quarterly investor webinar to be hosted by CEO Dr Luke Reid on 30 April 2026. The webinar will be accessible via the company’s interactive investor ...
Microba Rides Testing Surge, Eyes Deal and New Diagnostic Launch
Apr 30, 2026
Microba Life Sciences reported strong growth in its core testing business for the March quarter, with core test volumes up 58% year-on-year and an annualised run rate above 23,000 tests, driven largely by enterprise-style clinic accounts. In Austr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.